Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.36 |
| ▸ | GCGR | P47871 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.34 |
| ▸ | FABP3 | P05413 | 6/20 | 0.33 |
| ▸ | PPARD | Q03181 | 4/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | FABP7 | O15540 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | GCG | P01275 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036236 | 0.98 | MLYCD (0.35) | MLYCDGCGRHDAC4LTB4RFABP3 | |
| SCHEMBL6034689 | 0.90 | PPARD (0.36) | GCGRHDAC4LTB4RFABP3PPARD | |
| SCHEMBL6036397 | 0.90 | GCGR (0.36) | MLYCDGCGRHDAC4LTB4RPPARD | |
| SCHEMBL6036403 | 0.89 | GCGR (0.36) | MLYCDGCGRHDAC4LTB4RL3MBTL1 | |
| SCHEMBL6036323 | 0.88 | LTB4R (0.38) | GCGRLTB4RFABP3PPARDL3MBTL1 | |
| SCHEMBL1633424 | 0.88 | SMN1; SMN2 (0.37) | GCGRLTB4RFABP3PPARDFABP5 | |
| SCHEMBL6035370 | 0.88 | GCGR (0.37) | GCGRHDAC4LTB4RFABP3PPARD | |
| SCHEMBL6036332 | 0.88 | GCGR (0.36) | MLYCDGCGRHDAC4LTB4RPPARD | |
| SCHEMBL6035191 | 0.86 | MRGPRX4 (0.35) | GCGRLTB4RFABP3PPARDFABP5 | |
| SCHEMBL6035372 | 0.85 | PPARD (0.36) | GCGRLTB4RPPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | MLYCD 962/4885GCGR 93/4885HDAC4 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.